Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"

被引：7

作者：

Coutzac, Clelia ^{[1
,2
]}

Trouilloud, Isabelle ^{[3
]}

Pascal, Artru ^{[4
]}

Henriques, Julie ^{[5
]}

Masson, Therese ^{[6
]}

Doat, Solene ^{[7
]}

Bouche, Olivier ^{[8
]}

Coriat, Romain ^{[9
]}

Saint, Angelique ^{[10
]}

Moulin, Valerie ^{[11
]}

Vernerey, Dewi ^{[6
]}

Gallois, Claire ^{[1
]}

De La Fouchardiere, Christelle ^{[2
]}

Tougeron, David ^{[12
]}

Taieb, Julien ^{[1
]}

机构：

[1] Univ Paris, Hop Europeen Georges Pompidou, Paris, France

[2] Ctr Leon Berard, Lyon, France

[3] Hop St Antoine, Paris, France

[4] Private Hosp Jean Mermoz, Lyon, France

[5] Besancon Univ Hosp, Methodol & Qual Life Oncol Unit, Besancon, France

[6] CHU Poitiers, Dept Oncol Med, Poitiers, France

[7] Univ Hosp Pitie Salpetriere, APHP, Paris, France

[8] CHU Robert Debre, Reims, France

[9] Cochin Univ Hosp, Paris, France

[10] Ctr Antoine Lacassagne, Nice, France

[11] CH La Rochelle, La Rochelle, France

[12] CHU Poitiers, Dept Hepato Gastroenterol, Poitiers, France

来源：

CLINICAL COLORECTAL CANCER | 2022年 / 21卷 / 02期

关键词：

metastatic colorectal cancer; trifluridine/tipiracil; regorafenib; 1ST-LINE TREATMENT; BEVACIZUMAB; MULTICENTER; THERAPY; FOLFIRI;

D O I：

10.1016/j.clcc.2021.12.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It remains unclear which of regorafenib or trifluridine/tipiracil should be administered first in heavily pre-treated metastatic colorectal cancer patients. In this prospective multicenter real-world study, survival was similar in the regorafenib, and trifluridine-tipiracil groups. Using propensity score, PFS was significantly longer in the trifluridine-tipiracil group, whereas clinical outcomes seem to be similar regardless of the trifluridinetipiracil/regorafenib or regorafenib/trifluridine-tipiracil treatment sequence. Introduction: Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies. However, it remains unclear which drug should be administered first. Patients and Methods: This French observational study was prospectively conducted in 11 centers between June 2017 and September 2019. All consecutive patients with chemorefractory mCRC and receiving FTD/TPI and/or R were eligible. The aim was to evaluate the efficacy and tolerability of FTD/TPI and/or R in real-world setting with adjusted analysis. Results: A total of 237 mCRC patients (25% R and 75% FTD/TPI) were enrolled. As compared to R, FTD/TPI patients were significantly older and with more metastatic sites. Median OS and PFS were respectively 6.2 and 2.4 months in the FTD/TPI and 6.6 and 2.1 months in the R group. After matching 46 paired patients according to a propensity score, a trend to a longer OS (P = .58), and a significantly longer PFS (P = .048) were observed in the FTD/TPI group. In the 24% of patients receiving the R/T or T/R sequence, median OS from first treatment was similar. Tolerability profiles were similar to published data and dose reductions were more frequent in the R group. Conclusion: Efficacy and safety results in this real-world prospective study are in line with phase III trials. In a matched population, PFS was significantly longer in the FTD/TPI group. Despite a limited number of patients, clinical outcomes seemed similar in patients treated with the T/R or R/T sequence. (C) 2021 Elsevier Inc. All rights reserved.

引用

页码：132 / 140

页数：9

共 19 条

[1] Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program [J].

Adenis, Antoine ;

de la Fouchardiere, Christelle ;

Paule, Bernard ;

Burtin, Pascal ;

Tougeron, David ;

Wallet, Jennifer ;

Dourthe, Louis-Marie ;

Etienne, Pierre-Luc ;

Mineur, Laurent ;

Clisant, Stephanie ;

Phelip, Jean-Marc ;

Kramar, Andrew ;

Andre, Thierry .

BMC CANCER, 2016, 16

[2] Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study [J].

Bekaii-Saab, Tanios S. ;

Ou, Fang-Shu ;

Ahn, Daniel H. ;

Boland, Patrick M. ;

Ciombor, Kristen K. ;

Heying, Erica N. ;

Dockter, Travis J. ;

Jacobs, Nisha L. ;

Pasche, Boris C. ;

Cleary, James M. ;

Meyers, Jeffrey P. ;

Desnoyers, Rodwige J. ;

McCune, Jeannines ;

Pedersen, Katrina ;

Barzi, Afsaneh ;

Chiorean, E. Gabriela ;

Sloan, Jeffrey ;

Lacouture, Mario E. ;

Lenz, Heinz-Josef ;

Grothey, Axel .

LANCET ONCOLOGY, 2019, 20 (08) :1070-1082

[3] Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial [J].

Cremolini, Chiara ;

Rossini, Daniele ;

Dell'Aquila, Emanuela ;

Lonardi, Sara ;

Conca, Elena ;

Del Re, Marzia ;

Busico, Adele ;

Pietrantonio, Filippo ;

Danesi, Romano ;

Aprile, Giuseppe ;

Tamburini, Emiliano ;

Barone, Carlo ;

Masi, Gianluca ;

Pantano, Francesco ;

Pucci, Francesca ;

Corsi, Domenico C. ;

Pella, Nicoletta ;

Bergamo, Francesca ;

Rofi, Eleonora ;

Barbara, Cecilia ;

Falcone, Alfredo ;

Santini, Daniele .

JAMA ONCOLOGY, 2019, 5 (03) :343-350

[4] Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program [J].

Cremolini, Chiara ;

Rossini, Daniele ;

Martinelli, Erika ;

Pietrantonio, Filippo ;

Lonardi, Sara ;

Noventa, Silvia ;

Tamburini, Emiliano ;

Frassineti, Giovanni Luca ;

Mosconi, Stefania ;

Nichetti, Federico ;

Murgioni, Sabina ;

Troiani, Teresa ;

Borelli, Beatrice ;

Zucchelli, Gemma ;

Dal Maso, Alessandro ;

Sforza, Vincenzo ;

Masi, Gianluca ;

Antoniotti, Carlotta ;

Di Bartolomeo, Maria ;

Miceli, Rosalba ;

Ciardiello, Fortunato ;

Falcone, Alfredo .

ONCOLOGIST, 2018, 23 (10) :1178-1187

[5] Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study [J].

Ducreux, Michel ;

Petersen, Lone Norgard ;

Oehler, Leopold ;

Bergamo, Francesca ;

Metges, Jean-Philippe ;

de Groot, Jan Willem ;

Wang, Jaw-Yuan ;

Garcia Paredes, Beatriz ;

Dochy, Emmanuelle ;

Fiala-Buskies, Sabine ;

Cervantes, Andres ;

Manuel O'Connor, Juan ;

Falcone, Alfredo .

EUROPEAN JOURNAL OF CANCER, 2019, 123 :146-154

[6] Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].

Grothey, Axel ;

Van Cutsem, Eric ;

Sobrero, Alberto ;

Siena, Salvatore ;

Falcone, Alfredo ;

Ychou, Marc ;

Humblet, Yves ;

Bouche, Olivier ;

Mineur, Laurent ;

Barone, Carlo ;

Adenis, Antoine ;

Tabernero, Josep ;

Yoshino, Takayuki ;

Lenz, Heinz-Josef ;

Goldberg, Richard M. ;

Sargent, Daniel J. ;

Cihon, Frank ;

Cupit, Lisa ;

Wagner, Andrea ;

Laurent, Dirk .

LANCET, 2013, 381 (9863) :303-312

[7] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].

Heinemann, Volker ;

von Weikersthal, Ludwig Fischer ;

Decker, Thomas ;

Kiani, Alexander ;

Vehling-Kaiser, Ursula ;

Al-Batran, Salah-Eddin ;

Heintges, Tobias ;

Lerchenmueller, Christian ;

Kahl, Christoph ;

Seipelt, Gernot ;

Kullmann, Frank ;

Stauch, Martina ;

Scheithauer, Werner ;

Hielscher, Joerg ;

Scholz, Michael ;

Mueller, Sebastian ;

Link, Hartmut ;

Niederle, Norbert ;

Rost, Andreas ;

Hoeffkes, Heinz-Gert ;

Moehler, Markus ;

Lindig, Reinhard U. ;

Modest, Dominik P. ;

Rossius, Lisa ;

Kirchner, Thomas ;

Jung, Andreas ;

Stintzing, Sebastian .

LANCET ONCOLOGY, 2014, 15 (10) :1065-1075

[8] Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer [J].

Loupakis, Fotios ;

Cremolini, Chiara ;

Masi, Gianluca ;

Lonardi, Sara ;

Zagonel, Vittorina ;

Salvatore, Lisa ;

Cortesi, Enrico ;

Tomasello, Gianluca ;

Ronzoni, Monica ;

Spadi, Rosella ;

Zaniboni, Alberto ;

Tonini, Giuseppe ;

Buonadonna, Angela ;

Amoroso, Domenico ;

Chiara, Silvana ;

Carlomagno, Chiara ;

Boni, Corrado ;

Allegrini, Giacomo ;

Boni, Luca ;

Falcone, Alfredo .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17) :1609-1618

[9] Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer [J].

Masuishi, Toshiki ;

Taniguchi, Hiroya ;

Kawakami, Takeshi ;

Kawamoto, Yasuyuki ;

Kadowaki, Shigenori ;

Onozawa, Yusuke ;

Muranaka, Tetsuhito ;

Tajika, Masahiro ;

Yasui, Hirofumi ;

Nakatsumi, Hiroshi ;

Yuki, Satoshi ;

Muro, Kei ;

Omae, Katsuhiro ;

Komatsu, Yoshito ;

Yamazaki, Kentaro .

ESMO OPEN, 2019, 4 (06)

[10] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer [J].

Mayer, Robert J. ;

Van Cutsem, Eric ;

Falcone, Alfredo ;

Yoshino, Takayuki ;

Garcia-Carbonero, Rocio ;

Mizunuma, Nobuyuki ;

Yamazaki, Kentaro ;

Shimada, Yasuhiro ;

Tabernero, Josep ;

Komatsu, Yoshito ;

Sobrero, Alberto ;

Boucher, Eveline ;

Peeters, Marc ;

Tran, Ben ;

Lenz, Heinz-Josef ;

Zaniboni, Alberto ;

Hochster, Howard ;

Cleary, James M. ;

Prenen, Hans ;

Benedetti, Fabio ;

Mizuguchi, Hirokazu ;

Makris, Lukas ;

Ito, Masanobu ;

Ohtsu, Atsushi .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20) :1909-1919

← 1 2 →